



ALK  
Investor Relations Department  
BÅge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)

Sign-up for Email alerts [↗](#)

#### OMX: ALKB

Last Trade:	1024.00
Trade Time:	4:59 PM ET Jun 22, 2017
Change:	27.50 <span style="color: green;">▲</span> (+2.760%)
Day Range	998.00 - 1028.00
52-Week Range	839.00 - 1224.00
Volume	1,522,600

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Jun 1, 2017*

[Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer](#)

*Jun 1, 2017*

[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

*May 9, 2017*

[Three-month interim report \(Q1\) 2017](#)

*May 4, 2017*

[ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada](#)

*May 3, 2017*

[Release date of three-month interim report \(Q1\) 2017 and audio cast](#)

## Upcoming Events [\[ View all \]](#)

*Aug 16, 2017*

[Six-month interim report \(Q2\) 2017](#)

*Sep 8, 2017*

[Goldman Sachs Annual Biotech Symposium, London](#)